[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Malik et al., 2000 - Google Patents

Chronic hepatitis B virus infection: treatment strategies for the next millennium

Malik et al., 2000

Document ID
10417280805560082848
Author
Malik A
Lee W
Publication year
Publication venue
Annals of internal medicine

External Links

Snippet

Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma worldwide. Its prevalence approaches 10% in hyperendemic areas, such as southeast Asia, China, and Africa. Although chronic HBV infection is seen less frequently in …
Continue reading at www.acpjournals.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Malik et al. Chronic hepatitis B virus infection: treatment strategies for the next millennium
Konerman et al. Interferon treatment for hepatitis B
Tan et al. When hepatitis B virus meets interferons
Hadziyannis et al. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment
Hadziyannis et al. Treatment of HBeAg-negative chronic hepatitis B
Wong et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis
Pramoolsinsup Management of viral hepatitis B
HOOFNAGLE et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
Liaw et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
Papatheodoridis et al. Current management of chronic hepatitis B
Hadziyannis et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen–negative chronic hepatitis B
Cooksley et al. Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B
Wong et al. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
Zoulim Antiviral therapy of chronic hepatitis B
Kao HB eAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Soriano et al. Hepatitis delta and HIV infection
Suk‐Fong Lok Hepatitis B: 50 years after the discovery of Australia antigen
Ward et al. Treatment of hepatitis B virus: an update
Soriano et al. Emerging challenges in managing hepatitis B in HIV patients
Zhao et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy
Lindh et al. Treatment of chronic hepatitis B infection: an update of Swedish recommendations
Saikia et al. Management of patients with HBeAg-negative chronic hepatitis B
Rivkina et al. Chronic hepatitis B: current and future treatment options
Menne et al. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection
Clemente et al. An update on the strategies used for the treatment of chronic hepatitis B in children